Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives
EN Imyanitov, AG Iyevleva, EV Levchenko - Critical reviews in oncology …, 2021 - Elsevier
Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …
EGFR signaling pathway as therapeutic target in human cancers
Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
Protein tyrosine kinases of the human epidermal growth factor receptor family, including
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
EGFR and HER2, have emerged as important therapeutic targets in non-small-cell lung …
[HTML][HTML] ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …
by the ESMO, including 34 experts from 18 countries.•The experts compiled …
[HTML][HTML] Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations
The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …
[HTML][HTML] The molecular profiling of solid tumors by liquid biopsy: A position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies
A Russo, L Incorvaia, M Del Re, U Malapelle… - ESMO open, 2021 - Elsevier
The term liquid biopsy (LB) refers to the use of various biological fluids as a surrogate for
neoplastic tissue to achieve information for diagnostic, prognostic and predictive purposes …
neoplastic tissue to achieve information for diagnostic, prognostic and predictive purposes …
[HTML][HTML] Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
Compound epidermal growth factor receptor (EGFR) mutations represent a heterogeneous
subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations …
subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations …
[HTML][HTML] Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
Y Li, T Mao, J Wang, H Zheng, Z Hu, P Cao… - Cell Communication and …, 2023 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is currently the
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …
standard first-line therapy for EGFR-mutated advanced non-small cell lung cancer (NSCLC) …
[HTML][HTML] The emerging therapeutic landscape of ALK inhibitors in non-small cell lung cancer
V Gristina, M La Mantia, F Iacono, A Galvano, A Russo… - Pharmaceuticals, 2020 - mdpi.com
The treatment of metastatic non-small cell lung cancer (NSCLC) has undergone a paradigm
shift over the last decade. Better molecular characterization of the disease has led to the …
shift over the last decade. Better molecular characterization of the disease has led to the …
[HTML][HTML] Cancer therapy guided by mutation tests: current status and perspectives
SN Aleksakhina, EN Imyanitov - International journal of molecular …, 2021 - mdpi.com
The administration of many cancer drugs is tailored to genetic tests. Some genomic events,
eg, alterations of EGFR or BRAF oncogenes, result in the conformational change of the …
eg, alterations of EGFR or BRAF oncogenes, result in the conformational change of the …